Antigen Detection Assays
There are three main types of influenza virus (Types A,
B and C) that cause infection in humans and these
are further characterized into subtypes and strains. The
continued emergence of new flu strains each year is
due to the ability of a flu virus to mutate slowly (through
small genetic changes called antigenic drift) and quickly
through a process called reassortment. Antigenic drift is
responsible for the seasonal variations every year and
reassortment is responsible for the development of new
strains that can cause pandemics.
Influenza type A (Flu A) viruses are especially prone to reassortment due to their wide host range (humans, dogs, birds, pigs, horses, whales, seals and other animals). Specifically, the Flu A genome is made up of eight loosely linked segments, each of which harbors at least one important gene. Those genes direct the expression of the major viral proteins such as hemagglutinin (HA) and neuraminadase (NA). In the process of viral reproduction, the linkages between the eight segments of the Flu A genome break apart. Since it is possible for two different Flu A strains to infect a cell simultaneously, some of the genetic segments from one strain can be swapped with another during reproduction. For instance, if a human flu virus and a bird flu virus infect a person, reassortment can intermingle genes from both viruses during replication and create a virus with a protein against which humans have little or no immunity, plus human influenza genes that are more likely to cause sustained human-to-human transmission. In contrast, Influenza B (Flu B) and C viruses do not cause pandemics, most likely due to their limited host range of only humans.
Flu A virus is the most common flu virus infecting humans, animals, and birds. It is divided into subtypes, based on the nature of their surface glycoproteins, HA and NA. There are 18 different HAs and 11 NAs which are distinguishable serologically (antibodies to one virus subtype do not react with another). In comparison, Flu B infection mostly occurs in humans and it is divided into lineages and strains. Currently circulating influenza B viruses belong to one of the two lineages: B/Victoria and B/Yamagata. This virus is responsible for significant morbidity which is why the seasonal trivalent influenza vaccine contains Flu B as an integral component. Unlike Flu A or B, Influenza C viruses only cause a mild respiratory illness in humans and secondary complications are rare. Flu C is structurally different to Flu A and B viruses and contains a glycoprotein called HEF (hemagglutinin-esterase-fusion). Influenza viruses are mostly spread by aerosolization made when an infected person coughs or sneezes. Complications usually arise from bacterial infections of the lower respiratory tract and signs of a secondary respiratory infection often appear just as the infected person seems to be recovering. The elderly and the chronically ill are at greater risk for secondary infection and other complications. Children can also experience a rare, but serious complication called Reye’s syndrome
Diagnostic influenza tests help the identification of influenza types A and B and influenza A subtypes 2009 H1N1, H1, H3, H5, N1, and N2. Influenza tests include rapid influenza diagnostic tests (RIDTs), direct fluorescent antibody stains, viral cultures and molecular assays.
RIDTs have become routine influenza tests since their initial FDA approval in 1999, and they typically detect both Type A and B influenza. They are easy to use, relatively inexpensive, and provide rapid results in 10-30 minutes, allowing physicians to prescribe antivirals in the relatively small window of effectiveness (1-2 days after onset of symptoms). The performance of RIDTs is highly dependent on the quality of reagents, proficiency of operation, transport and storage conditions, time from illness onset to sample collection and the emergence of genomic variations and novel strains. Many RIDTs detect the nucleoprotein (NP), which is one of the more conserved proteins in the influenza virus and subsequently less likely to undergo mutations that lead to antigenic drift (which in turn can cause the functional components of an RIDT to not recognize a current influenza strain). The major limitation of currently available RIDTs is their low and variable sensitivity. To obtain a true increase in assay sensitivity, monoclonal antibodies capable of recognizing existing and emerging strains are critical.
INFLUENZA B - REAGENTS FOR SEROLOGIC TESTING
INFLUENZA B - REAGENTS FOR SEROLOGIC TESTING (cont)
INFLUENZA B - REACTIVITY DATA
Current circulating influenza B strains are changing profile. The World Health Organization (WHO) analysis of
circulating influenza B strains has revealed that while Victoria lineage viruses are prevalent in some countries, the
proportion of Yamagata lineage ones continue to increase and are becoming dominant in many countries. Patterns
with the genetic clades showed that many viruses in clade 2, which includes B/Massachusetts/2/2012, were
antigenically distinct from those in clade 3, which includes B/Wisconsin/1/2010. As a result WHO recommends
including B/Massachusetts/2/2012, in replacement of B/Wisconsin/1/2010, and a B/Brisbane/60/2008-like virus
starting from the 2013-14 season.
The following antibodies have been tested against a panel of influenza subtype nucleoproteins using a immunoprecipitation-equivalent method to determine their reactivity to a particular strain. The higher the percentage, the stronger the reactivity of the antibody.